Advertisement

Molecular Cancer

, 18:79 | Cite as

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

  • Simar Pal Singh
  • Floris Dammeijer
  • Rudi W. HendriksEmail author
Open Access
Correction
  • 265 Downloads

Correction to: Mol Cancer

https://doi.org/10.1186/s12943-018-0779-z

Following publication of the original article [1], the authors reported an error in Table 1. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row).The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.
Table 1

Clinical trials with BTK inhibitors in B cell malignancies

Patient population

Therapeutic regimen

Phase

Efficacy

Ref

R/R CLL

Ibrutinib

Ib/II

ORR (71%), PR (20%)

[11]

R/R CLL

Ibrutinib

III

ORR (63%)

[248]

TN CLL

Ibrutinib

Ib/II

ORR (85%), CR (26%)

[199]

TN CLL

Ibrutinib

III

ORR (86%), CR (4%)

[13]

R/R MCL

Ibrutinib

II

ORR (68%), CR (21%)

[187]

R/R MCL

Ibrutinib

III

ORR (72%), CR (19%)

[249]

R/R WM

Ibrutinib

II

ORR (91%), Major response (73%)

[188]

R/R ABC-DLBCL

Ibrutinib

II

ORR (37%)

[196]

R/R CLL

Ibrutinib-Rituximab

II

ORR (95%), CR (8%)

[250]

R/R CLL

Ibrutinib-bendamustine-rituximab

III

ORR (83%), CR (10%)

[251]

R/R MCL

Ibrutinib-Rituximab

II

ORR (88%), CR (44%), PR (44%)

[252]

R/R CLL

Acalabrutinib

I/II

ORR (95%)

[12]

R/R

Acalabrutinib

II

ORR (81%), CR (40%), PR (41%)

[219]

R/R CLL

ONO/GS-4059

I

ORR (96%)

[222]

R/R MCL

ONO/GS-4059

I

ORR (92%)

[222]

R/R non-GCB DLBCL

ONO/GS-4059

I

ORR (35%)

[222]

R/R CLL

BGB-3111

I

ORR (90%)

[221, 253]

R/R MCL

BGB-3111

I

ORR (80%)

[253]

R/R MZL

Ibrutinib

II

ORR (51%)

[254]

R/R FL

Ibrutinib

I

ORR (38%)

[186]

CLL Chronic Lymphocytic leukemia, MCL Mantle cell lymphoma, WM Waldenström’s Macroglobulinemia, ABC-DLBCL Activated B-cell Diffuse large B cell Lymphoma, MZL Marginal zone lymphoma, FL Follicular lymphoma, R/R relapsed or refractory, TN treatment-naïve, ORR overall response rate, CR complete response, PR partial response, Major response: complete response or at least 50% reduction in serum IgM levels

Reference

  1. 1.
    Singh PS, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cellsand malignancies. Mol Cancer. 2018;17:57  https://doi.org/10.1186/s12943-018-0779-z.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Simar Pal Singh
    • 1
    • 2
    • 3
  • Floris Dammeijer
    • 1
    • 3
    • 4
  • Rudi W. Hendriks
    • 1
    Email author
  1. 1.Department of Pulmonary MedicineRotterdamThe Netherlands
  2. 2.Department of ImmunologyRotterdamThe Netherlands
  3. 3.Post graduate school Molecular MedicineRotterdamThe Netherlands
  4. 4.Erasmus MC Cancer Institute, Erasmus MCRotterdamThe Netherlands

Personalised recommendations